MedTrace Logo

A Clinical Trial of PEGIFNα1b in Chinese Healthy Adults

NCT05639803 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2022-12-06

No results posted yet for this study

Summary

This is a Phase I，randomized, double-blind, placebo controlled,dose escalated,single administrated clinical trial in Chinese healthy adult's volunteers.

In the trial, it is planned to enroll 50 subjects, randomized to 5 dosage groups to receive the test drug and the placebo control.

Conditions

  • Herpes Zoster

Interventions

DRUG

PEGIFNα1b

100μg/vial

DRUG

Placebo

0.5ml/vial

Sponsors & Collaborators

  • Shanghai Institute Of Biological Products

    lead INDUSTRY

Principal Investigators

  • Shanghai Institute Of Biological Products Co., Ltd · SINOPHARM

  • The first affiliated hospital of bengbu medical college · Bengbu medical college

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-07-07
Primary Completion
2020-10-22
Completion
2020-10-22

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05639803 on ClinicalTrials.gov